
|Videos|September 29, 2022
Dr. Joyce on financial toxicity and advanced prostate cancer treatments
Author(s)Urology Times staff
“We really need to be thoughtful about how our treatment recommendations may induce financial toxicity in patients with advanced prostate cancer,” says Daniel D. Joyce, MD.
Advertisement
In this video, Daniel D. Joyce, MD, discusses the take-home message from the recent Journal of Urology study, “Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients,” for which he served as a study author. Joyce is a urologic oncology fellow at Mayo Clinic, Rochester, Minnesota.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves sildenafil oral film for men with erectile dysfunction
2
The UroOnc Minute: Adjuvant Therapy in Renal Cell Carcinoma, with Brian Shuch, MD
3
Head-to-head analysis shows OS benefit with apalutamide vs darolutamide in mCSPC
4
Pearls & Perspectives: Modern Semen Testing and Male Fertility Care, with Thomas Masterson, MD
5






